Luther R R, Glassman H N, Jordan D C, Sperzel W D
Am J Med. 1986 May 23;80(5B):73-6. doi: 10.1016/0002-9343(86)90856-9.
A total of 713 patients with hypertension were evaluated in eight randomized, double-blind, placebo-controlled trials of terazosin administered in single daily doses ranging from 1 to 40 mg. In three of these studies, terazosin or placebo was added to ongoing antihypertensive drug therapy. Patient response was categorized (from excellent to inadequate) according to the change in supine diastolic blood pressure from baseline and the value at the final visit. The distribution of patients in these response categories differed significantly between patients treated with terazosin and those treated with placebo. Overall, 52 percent of terazosin-treated patients in these eight studies, compared with 30 percent of placebo-treated patients, had good to excellent responses. Subgroup analysis revealed that blood pressure response was not dependent on sex or age, although white patients appeared to achieve better responses to terazosin in comparison with placebo than did black patients. These studies demonstrate that terazosin administered once daily, either as monotherapy or in combination with other antihypertensive agents, effectively controls blood pressure in patients with mild to moderate hypertension.
在八项随机、双盲、安慰剂对照试验中，对总共713例高血压患者进行了评估，这些试验使用的是每日单次剂量为1至40毫克的特拉唑嗪。在其中三项研究中，将特拉唑嗪或安慰剂添加到正在进行的抗高血压药物治疗中。根据仰卧位舒张压相对于基线的变化以及最后一次就诊时的值，将患者反应分类（从优到差）。接受特拉唑嗪治疗的患者和接受安慰剂治疗的患者在这些反应类别中的分布存在显著差异。总体而言，在这八项研究中，52%接受特拉唑嗪治疗的患者反应良好至极佳，而接受安慰剂治疗的患者这一比例为30%。亚组分析显示，血压反应不取决于性别或年龄，尽管与安慰剂相比，白人患者使用特拉唑嗪似乎比黑人患者有更好的反应。这些研究表明，特拉唑嗪每日服用一次，无论是作为单一疗法还是与其他抗高血压药物联合使用，都能有效控制轻度至中度高血压患者的血压。
